Manuel Antonio Prieto1, Omar Prieto2, Horacio Matias Castro3. 1. Central de Emergencias de Adultos. Hospital Italiano de San Justo Agustín Rocca, Buenos Aires, Argentina.. manuel.prieto@hospitalitaliano.org.ar. 2. Docente de la Universidad de Buenos Aires. omarprieto@hotmail.com. 3. Sección de Neumonologia, Hospital Italiano de Buenos Aires, Argentina. . matias.castro@hospitalitaliano.org.ar.
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is a public health problem worldwide. After 3 weeks of the onset of the disease, between 10-87% of patients persist with symptoms. The objective of the study was to evaluate the persistence of symptoms in patients with COVID-19, the associated factors, and to explore the patients' perception of the disease. Materials and methods: We conducted a cross-sectional study that included 85 patients with a confirmed diagnosis of COVID-19, who attended on an outpatient basis after the acute phase (> 3 weeks) of the disease. Results: The median time from diagnosis to outpatient consultation was 53 days (interquartile range 31-65). Most (86%) had mild disease, 45% were women and the mean age was 43 years (standard deviation of 13). After the acute phase of the disease 52% (95% CI 41-63%) of the patients persisted with symptoms. The most frequently persistent symptoms were fatigue (49%) and cough (33%). Nineteen percent had insomnia and sixteen percent had anxiety. Female sex, obesity, age between 35-55 years, and initial hospitalization were associated with the persistence of symptoms. Twenty percent of the patients stopped following the prevention recommendations because they believed they were immunized. Conclusion: More than half of the patients persisted with symptoms 3 weeks after the COVID-19 diagnosis, so medical follow-up is important. Female sex, obesity, age 35-55 years, and initial hospitalization were associated factors. The symptoms usually resolved over time. Universidad Nacional de Córdoba
Introduction: Coronavirus disease 2019 (COVID-19) is a public health problem worldwide. After 3 weeks of the onset of the disease, between 10-87% of patients persist with symptoms. The objective of the study was to evaluate the persistence of symptoms in patients with COVID-19, the associated factors, and to explore the patients' perception of the disease. Materials and methods: We conducted a cross-sectional study that included 85 patients with a confirmed diagnosis of COVID-19, who attended on an outpatient basis after the acute phase (> 3 weeks) of the disease. Results: The median time from diagnosis to outpatient consultation was 53 days (interquartile range 31-65). Most (86%) had mild disease, 45% were women and the mean age was 43 years (standard deviation of 13). After the acute phase of the disease 52% (95% CI 41-63%) of the patients persisted with symptoms. The most frequently persistent symptoms were fatigue (49%) and cough (33%). Nineteen percent had insomnia and sixteen percent had anxiety. Female sex, obesity, age between 35-55 years, and initial hospitalization were associated with the persistence of symptoms. Twenty percent of the patients stopped following the prevention recommendations because they believed they were immunized. Conclusion: More than half of the patients persisted with symptoms 3 weeks after the COVID-19 diagnosis, so medical follow-up is important. Female sex, obesity, age 35-55 years, and initial hospitalization were associated factors. The symptoms usually resolved over time. Universidad Nacional de Córdoba
Entities:
Keywords:
COVID-19; SARS-CoV-2; symptoms, fatigue; follow up studies
Authors: Michael C Grant; Luke Geoghegan; Marc Arbyn; Zakaria Mohammed; Luke McGuinness; Emily L Clarke; Ryckie G Wade Journal: PLoS One Date: 2020-06-23 Impact factor: 3.240
Authors: David T Arnold; Fergus W Hamilton; Alice Milne; Anna J Morley; Jason Viner; Marie Attwood; Alan Noel; Samuel Gunning; Jessica Hatrick; Sassa Hamilton; Karen T Elvers; Catherine Hyams; Anna Bibby; Ed Moran; Huzaifa I Adamali; James William Dodd; Nicholas A Maskell; Shaney L Barratt Journal: Thorax Date: 2020-12-03 Impact factor: 9.139